Nephro Care India Ltd
Incorporated in 2014, Nephro Care India Ltd is a healthcare provider that specializes
in the treatment of kidney- related diseases[1]
- Market Cap ₹ 122 Cr.
- Current Price ₹ 73.9
- High / Low ₹ 183 / 50.0
- Stock P/E 36.2
- Book Value ₹ 34.5
- Dividend Yield 0.00 %
- ROCE 8.70 %
- ROE 6.11 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.7% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 0.54 | 1.82 | 3.42 | 17.09 | 27.23 | 46.03 | 88.73 | |
| 0.52 | 1.67 | 3.28 | 13.66 | 20.76 | 40.16 | 80.41 | |
| Operating Profit | 0.02 | 0.15 | 0.14 | 3.43 | 6.47 | 5.87 | 8.32 |
| OPM % | 3.70% | 8.24% | 4.09% | 20.07% | 23.76% | 12.75% | 9.38% |
| 0.01 | 0.01 | -0.01 | 0.00 | 0.28 | 1.53 | 1.55 | |
| Interest | 0.04 | 0.03 | 0.02 | 0.07 | 0.09 | 0.11 | 0.16 |
| Depreciation | 0.00 | 0.01 | 0.11 | 0.78 | 0.53 | 2.46 | 5.07 |
| Profit before tax | -0.01 | 0.12 | 0.00 | 2.58 | 6.13 | 4.83 | 4.64 |
| Tax % | 0.00% | 25.00% | 7.75% | 28.06% | 24.64% | 27.37% | |
| -0.01 | 0.09 | -0.01 | 2.37 | 4.41 | 3.64 | 3.37 | |
| EPS in Rs | -10.00 | 90.00 | -0.20 | 47.40 | 3.71 | 2.21 | 2.04 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 118% |
| 3 Years: | 73% |
| TTM: | 93% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 106% |
| 3 Years: | 12% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -44% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 11% |
| Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.50 | 0.50 | 11.90 | 16.49 | 16.49 |
| Reserves | 0.07 | 0.01 | 0.00 | 2.03 | 3.12 | 37.00 | 40.37 |
| 0.40 | 0.69 | 2.54 | 2.48 | 0.00 | 0.00 | 0.00 | |
| 0.30 | 0.42 | 1.60 | 3.25 | 5.94 | 14.79 | 15.81 | |
| Total Liabilities | 0.78 | 1.13 | 4.64 | 8.26 | 20.96 | 68.28 | 72.67 |
| 0.45 | 0.06 | 1.39 | 3.01 | 4.74 | 31.48 | 34.12 | |
| CWIP | 0.00 | 0.45 | 1.90 | 0.00 | 0.86 | 0.61 | 0.43 |
| Investments | 0.24 | 0.00 | 0.00 | 2.00 | 6.51 | 18.58 | 11.82 |
| 0.09 | 0.62 | 1.35 | 3.25 | 8.85 | 17.61 | 26.30 | |
| Total Assets | 0.78 | 1.13 | 4.64 | 8.26 | 20.96 | 68.28 | 72.67 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 0.23 | 0.62 | 4.12 | 0.91 | 7.82 | 2.21 | ||
| -0.06 | -2.81 | -2.33 | -7.54 | -39.56 | -0.48 | ||
| 0.28 | 2.32 | -0.08 | 5.60 | 35.10 | 0.00 | ||
| Net Cash Flow | 0.44 | 0.13 | 1.71 | -1.03 | 3.37 | 1.73 | |
| Free Cash Flow | 0.16 | -2.28 | 3.62 | -2.38 | -21.98 | -5.59 | |
| CFO/OP | 133% | 493% | 121% | 50% | 154% | 48% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 20.28 | 0.85 | 2.01 | 25.61 | 24.85 |
| Inventory Days | 8.83 | 41.93 | 35.25 | 14.07 | 34.38 | 31.68 | |
| Days Payable | 94.19 | 113.45 | 69.03 | 75.17 | 107.32 | 92.84 | |
| Cash Conversion Cycle | 0.00 | -85.36 | -51.24 | -32.93 | -59.09 | -47.33 | -36.31 |
| Working Capital Days | -168.98 | -88.24 | -124.87 | -56.81 | -36.86 | -51.23 | 37.10 |
| ROCE % | 25.21% | 1.60% | 65.84% | 60.41% | 11.27% | 8.70% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Hospital Bed Capacity (Vivacity Hospital) Beds |
|
|
| Number of Clinics Facilities |
||
| Revenue from IPD Services Percentage share |
||
| Revenue from OPD Services Percentage share |
||
| Revenue from Pharmacy Sales Percentage share |
||
| Total Employees Count |
||
| Total Patients Treated Patients |
||
| Bed Occupancy Rate (Vivacity Hospital) % |
||
| OT Procedures (Vivacity Hospital) Procedures |
||
Extracted by Screener AI
Documents
Announcements
-
Related Party Transactions
27 May 2026 - Disclosed related party transactions for half year ended 31 March 2026.
-
Statement of deviation(s) or variation(s) under Reg. 32
27 May 2026 - Nephro Care India Limited has informed about statement of deviation(s) or variation(s) under Reg. 32
-
Outcome of Board Meeting
27 May 2026 - Board approved audited standalone/consolidated FY26 results and appointed M. Dutta & Associates internal auditor for FY27.
-
Capacity addition
18 April 2026 - Vivacity Clinic opened at Alipurduar, West Bengal on April 19, 2026, expanding healthcare services.
-
Structural Digital Database
14 April 2026 - Filed SDD compliance certificate for quarter ended 31 March 2026; no non-compliances observed.
Annual reports
Concalls
-
Aug 2025TranscriptAI SummaryPPT
Business Overview:[1][2]
NCIL provides comprehensive medical services for renal patients as a one-stop treatment center in Kolkata. It offers clinical and lifestyle solutions for renal insufficiency, covering lifestyle, physiological, and spiritual wellness. The company specializes in non-invasive services.